Vivoryon Therapeutics N.V. (AMS:VVY)

Market Cap	47.68M
Revenue (ttm)	n/a
Net Income (ttm)	-12.48M
Shares Out	29.61M
EPS (ttm)	-0.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,745
Average Volume	36,478
Open	1.600
Previous Close	1.600
Day's Range	1.590 - 1.610
52-Week Range	1.368 - 2.700
Beta	1.63
RSI	47.42
Earnings Date	Dec 4, 2025

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 14
• Stock Exchange: Euronext Amsterdam
• Ticker Symbol: VVY